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To the Editor,
The activated partial thromboplastin time (APTT) has 
been used for years for different purposes including 
screening for intrinsic factor deficiencies (FVIII, FIX, FXI 
and FXII) [1, 2]. The APTT factor sensitivity depends on 
reagent composition comprising the type of contact acti-
vator as well as the origin and composition of phospholip-
ids [3, 4]. Current guidelines recommend a prolongation of 
the APTT when factor levels are below 30% [5]. However, 
mild deficiencies above 30% can also imply a significant 
risk of bleeding [6, 7]. Prothrombin time (PT) is primarily 
used to monitor oral vitamin K antagonists (VKA). Again, 
different reagents are available with different sensitivities 
[8]. Literature is very scarce but Testa et al. demonstrated 
a discrepant sensitivity to FV, FVII, and FX of two PT 
re agents [8]. Different sources of thromboplastins (rabbit, 
human, recombinant) may influence the FVII dosage [9]. 
Equally, a prolongation of the PT when factor levels drop 
from 30% to 45% is recommended [5].
By the use of dilution series of normal frozen plasma 
and freeze-dried or frozen factor deficient plasmas, the 
responsiveness of different APTT reagents has been tested 
[4]. Lawrie et  al. suggested that lyophilized deficient 
plasmas may contain procoagulant material [10]. They 
concluded that determination of APTT factor sensitivity in 
accordance with the CLSI guidelines can give inconsistent 
and misleading results. The use of well-defined patient 
samples was recommended [10].
Reagent composition and laboratory equipment are 
the most important variables for observed differences 
in sensitivity. Every laboratory should assess their own 
factor sensitivities in order to correctly interpret their 
routine coagulation tests. In this study, we aim to evalu-
ate and compare the factor sensitivities in our daily prac-
tice by two appraoches: dilution experiments with normal 
pooled plasma (NPP) and in accordance with the CLSI 
guidelines by the use of patient deficient plasmas.
APTT (STA-PTTA, Diagnostica Stago, Asnières, France) 
and PT (Neoplastine CI Plus, Stago) were performed on the 
STA-R Evolution (Stago). One-stage-clotting assays were 
performed for intrinsic factors with STA-C.K. Prest (Stago) 
and for extrinsic factors with Neoplastine CI Plus (Stago), 
and by the use of lyophilized STA- Immunodeficient 
(STA-ID) (Stago) (FII, FVIII, FIX, FXI and FXII) and lyo-
philized STA-deficient (STA-D) (Stago) (FV, FVII, and FX) 
plasmas. In-house made NPP consisting of equal volumes 
of 80 healthy volunteers and stored at –80 °C was used for 
dilutions. Factor levels of NPP, STA-ID and STA-D plasmas 
were measured. Factor sensitivity of APTT (FVIII, FIX, FXI 
and FXI) and PT (FII, FV, FVII and FX) was assessed by 
two experiments. First, a spiking experiment was per-
formed by mixing increasing volumes of NPP with factor 
deficient plasma. A series of 10 samples with factor activi-
ties of 10% up to 100% was obtained. Second, an analog 
series of ±22 patient samples was selected for every factor 
(two different patients per level). If certain factor activities 
lacked, different samples were mixed. A limited number 
of patients with FX deficiency and no patients with FII 
deficiency were available. APTT (s) or PT (s) and the 
studied factor (%) were analyzed in duplicate whereas 
other intrinsic or extrinsic factors were analyzed in single. 
If factor levels were outside the reference range besides 
the studied factor, samples were excluded. A difference of 
5% for duplicates was accepted [5]. The factor sensitivity 
is defined as the level of factor from where on a prolonga-
tion of APTT or PT was observed. Factor sensitivities were 
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deduced graphically by evaluating the intersection of the 
upper limit of the reference range for APTT (38.1 s) or PT 
(16.5 s – in accordance with 70%) and the activity of the 
determined factor [5, 11]. The study was approved by the 
Ethical Committee of the Ghent University Hospital and 
was in accordance with the Declaration of Helsinki.
All deficient plasmas showed factor levels below or 
equal to 2% for the factor of interest, as shown in Table 1. 
Other factors were within the normal range, except for 
STA-D FV plasma with 178% FVII and 5% FVIII; the prepa-
ration of STA-D FV plasma by destabilization at room tem-
perature, may explain that other labile factors such as FVIII 
will also be affected. FV and FVII levels in STA-ID FXII were 
borderline. All factor levels of the NPP were normal.
Results of the spiking experiments shown as dark 
grey squares are depicted in Figure 1A and B for the intrin-
sic and extrinsic factors, respectively. The mean APTT 
or PT of the duplicate measurements was plotted on the 
y-axis, whereas the mean factor activity was plotted on the 
x-axis. Evaluation showed an intrinsic factor sensitivity of 
50% for FVIII, 52% for FIX, 65% for FXI and 46% for FXII, 
and an extrinsic factor sensitivity of 36% for FII, 36% for 
FV, 47% for FVII and 41% for FX. Factor sensitivity was 
also assessed by the use of patient samples, results are 
shown as light gray squares. Evaluation showed an intrin-
sic factor sensitivity of 55% for FVIII, 69% for FIX, 81% for 
FXI and 78% for FXII, and an extrinsic factor sensitivity of 
45% for FV, 56% for FVII and 53% for FX.
In summary, results of our spiking experiment showed 
that factor sensitivities of the APTT were all above the 
upper limit of the proposed range of 30%–45% [5]. 
Consequently, mild (50% FVIII, 52% FIX, 46% FXII) and 
for FXI very mild (65%) deficiencies can be detected. The 
STA-PTTA reagent is the least sensitive for FXII (46%) and 
the most for FXI (65%). As FXII deficiencies are not asso-
ciated with a bleeding tendency, and FXI levels do not 
correlate with bleeding risk, these findings are extremely 
useful. Patients with borderline FXI levels can present 
with a significant bleeding risk, therefore it is important 
to detect mild and very mild deficiencies [7]. In contrast to 
our finding, Bowyer et al. showed a FXI responsiveness for 
the STA-PTTA reagent of only 26 U/dL [4]. They used frozen 
immunodepleted FXI deficient plasma, commercial frozen 
NPP, and the CA7000 analyzer (Sysmex). These three varia-
bles lead to a contrasting result for FXI, again showing the 
importance of the whole setting. Besides, sensitivity ideally 
should be assessed by the use of patient deficient plasma 
[10]. Our experiments with patient plasmas showed mark-
edly higher factor sensitivities for FIX, FXI and FXII com-
pared to our spiking experiment. We cannot exclude that 
some of these discrepancies may be explained by factor 
deficiencies in the common coagulation pathway factors 
(FII, FV or FX). However, this seems very unlikely, since all 
samples originated from congenital single factor deficient 
patients. Though, results can be hampered by artifactial 
FV reduction due to pre-analytical sample quality.
Results for factor sensitivities of the PT were all in 
accordance with the CLSI guidelines [5]. The Neoplastine 
CI Plus reagent is the least sensitive for FII and FV (36%) 
and the most for FVII (47%). Very mild deficiencies will not 
be detected. Factor sensitivities established with patient 
samples are in accordance with the spiking experiment.
Table 1: Evaluation of the factor levels (%) in STA-Immunodeficient (STA-ID), STA-deficient (STA-D) plasmas and in-house made normal 
pooled plasma (NPP).
  FII   FV   FVII   FX   FVIII   FIX   FXI   FXII
Reference range (%)   70–120  70–120  70–130  70–120  60–150  60–150  60–140  60–150
STA-ID FII    < 1  78  85  79  70  118  89  90
STA-D FV   80  2  178  71  5  67  71  94
STA-D FVII   86  89  1  76  75  118  92  93
STA-D FX   81  77  91   < 1  70  108  91  92
STA-ID FVIII   82  81  73  75   < 0.3  94  78  73
STA-ID FIX   82  85  82  79  83  0.9  78  76
STA-ID FXI   93  87  86  89  75  93   < 0.4  71
STA-ID FXII   74  67  66  76  60  101  74  1
NPP   111  95  114  100  96  116  118  113
Levels not in accordance with the reference ranges are shown in bold. NPP, normal pooled plasma; STA-D, STA-deficient; STA-ID, STA-immu-
nodeficient. Shaded values correspond to the deficient factors of the commercial plasmas.
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Figure 1: APTT and PT factor activity.
(A) Evaluation of APTT factor sensitivity: FVIII, FIX, FXI and FXII. Results of the spiking experiment are shown as dark gray diamonds ( ), and 
results of the evaluation by patient samples are shown as light gray squares ( ). APTT, activated partial thromboplastin time. (B) Evaluation 
of PT factor sensitivity: FII, FV, FVII and FX. Results of the spiking experiment are shown as dark gray diamonds ( ), and results of the evalu-
ation by patient samples are shown as light gray squares ( ). PT, prothrombin time.
In conclusion, both the APTT (STA-PTTA) and the PT 
(Neoplastine CI Plus) tested in our setting show a very 
good factor sensitivity. Results obtained for PT sensitivity 
were comparable for both approaches. Discrepancy was 
observed only in the APTT. Collection, storage and avail-
ability of clinical samples are limitations in evaluating 
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factor sensitivity with patient samples. Spiking experi-
ments are easier to perform and more feasible for most 
laboratories. Of course, the results of this study should be 
carefully interpreted as factor sensitivity is depending on 
the whole laboratory setting.
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